ArticleCancer medicine2025
Cardiovascular Safety Landscape of ADT in Prostate Cancer Treatment Based on Real-World Analysis.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Cardiovascular Complications Associated with Uro-Oncology Treatments-A Primer for the Clinician.Diagnostics (Basel, Switzerland) · 2026Review
- Cardiovascular Safety Landscape of ADT in Prostate Cancer Treatment Based on Real-World Analysis.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundProstate cancer is among the most prevalent malignancies worldwide, and cardiovascular disease (CVD) is a major non-cancer cause of death in affected patients. Androgen deprivation therapy (ADT), a mainstay treatment, has raised concerns about cardiotoxicity, yet the CVD risks of individual ADT agents remain unclear.
objectivesTo assess cardiovascular adverse events (AEs) associated with specific ADT drugs using data from the U.S. FDA Adverse Event Reporting System (FAERS).
methodsAE reports related to ADT drugs were extracted from FAERS (Q1 2004-Q3 2024). Disproportionality analyses-including Reporting Odds Ratio (ROR) and Proportional Reporting Ratio (PRR)-were conducted to identify significant cardiovascular safety signals.
resultsDifferent ADT agents exhibited distinct cardiovascular AE profiles. Some drugs were linked to a broader range of CVD-related AEs, while others had more limited associations.
conclusionsADT agents demonstrate heterogeneous cardiotoxicity profiles. These findings emphasize the need for individualized treatment strategies, particularly in patients with pre-existing CVD risks, and may aid clinicians in balancing cancer control with cardiovascular safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.